Evidence mapPaperPMID 40563926Full record

ReviewBiology2025

Modified Lipid Particle Recognition: A Link Between Atherosclerosis and Cancer?

Amy E Hall, Dhananjay Jade, Faheem Shaik, Shervanthi Homer-Vanniasinkam, Stephen P Muench, Michael A Harrison, Sreenivasan Ponnambalam

Abstract readReview
In one paragraph

Review in Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Amy E HallSchool of Molecular & Cellular Biology, University of Leeds, Leeds LS2 9JT, UK.
Dhananjay JadeSchool of Molecular & Cellular Biology, University of Leeds, Leeds LS2 9JT, UK.ORCID 0000-0002-3009-5915
Faheem ShaikSchool of Molecular & Cellular Biology, University of Leeds, Leeds LS2 9JT, UK.
Shervanthi Homer-VanniasinkamDepartment of Mechanical Engineering, Division of Surgery, University College London, London WC1E 6BJ, UK.ORCID 0000-0001-6234-5053
Stephen P MuenchSchool of Biomedical Sciences, University of Leeds, Leeds LS2 9JT, UK.ORCID 0000-0001-6869-4414
Michael A HarrisonSchool of Biomedical Sciences, University of Leeds, Leeds LS2 9JT, UK.
Sreenivasan PonnambalamSchool of Molecular & Cellular Biology, University of Leeds, Leeds LS2 9JT, UK.ORCID 0000-0002-4452-7619

Funding

British Heart Foundation BHF/PG/25/12191
6 · The paper itself

Abstract

Cardiovascular disease and cancer are major global causes of mortality. Dysfunctional lipid metabolism causes atherosclerosis, a driving force in arterial disease leading to heart attacks and strokes. In this review, we focus on emerging evidence for links between atherosclerosis and cancer. In atherosclerosis, modified and oxidized lipid particles promote plaque initiation and progression, with wider effects on cell and tissue responses. Oxidized and modified lipid particles bind to scavenger receptors (SRs) and promote intracellular signaling and pro-inflammatory responses. Increasing evidence points to SR-mediated activation and signaling promoting cancer cell growth and spread. In particular, the lectin-like oxidized low-density lipoprotein (LOX-1) scavenger receptor activates NF-κB-regulated signal transduction pathways which modulate different cellular responses. LOX-1-regulated signaling events are implicated in both atherosclerosis and cancer, depending on the cell type. LOX-1 signaling modulates cell proliferation, epithelial-mesenchymal transition, neutrophil recruitment and apoptosis. Elevated LOX-1 levels are linked to poor prognosis in arterial disease and prostate, colorectal and lung cancers. Inhibition of LOX-1 function could thus provide new therapeutic strategies for targeting both atherosclerosis and cancer.

Indexed as

apoptosisatherosclerosiscancerinflammationlipid particleLOX-1proliferationscavenger receptorsignal transduction

Identifiers

PMID40563926
PMCPMC12189389

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.